$KALA

What Sparked KALA BIO's Nearly 38% Surge Overnight? - NovaBay Pharmaceuticals (AMEX:NBY), Kala Bio (NASDAQ:KALA)

KALA BIO Inc. ( NASDAQ:KALA ) jumped 37.87% to $0.88 in after-hours trading on Tuesday. Check out the current price of KALA stock here. According to Benzinga Pro data, the stock closed the regular session at $0.64, up 3.45%.

Original reporting
Benzinga · Mohd Haider
Published Nov 26, 2025, 5:34 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 26, 2025, 6:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What Sparked KALA BIO's Nearly 38% Surge Overnight? - NovaBay Pharmaceuticals (AMEX:NBY), Kala Bio (NASDAQ:KALA) — source image
Decision brief

The 30-second read

$KALABullishMed
01

Why it matters

The sudden price movement could lead to increased volatility and trading volume, affecting liquidity and risk levels.

02

Market read

While the move is significant for KALA, its impact on the broader biotech sector and markets is limited without corroborating news.

03

What to watch

Lack of detailed news or fundamental catalysts raises concerns about the sustainability of the price increase.

Timing: short-term (next few days)

Background

KALA BIO's stock surged dramatically after-hours, possibly due to undisclosed news or speculative trading activity.

Company-level read

Ticker impact

$KALABullishMedium confidence
Context

High relevance due to significant overnight price surge and recent news coverage.

Expected impact

Potential continued upward momentum in the short term, with possible correction after the initial surge.

Evidence & confidence

The substantial overnight gain indicates strong buying interest, but without specific news details, the sustainability of the move is uncertain.

Market effects

The biotech sector may experience increased attention, but the impact is limited to KALA due to lack of broader sector movement.

Minimal regional impact, primarily affecting US-based biotech stocks.

Low, as the news pertains to a specific company and sector.

Counterpoint

The surge may be a temporary spike driven by speculative trading, risking a swift reversal.

Key entities

  • KALA BIO Inc.

    A biotechnology company focusing on innovative therapies.

Related articles

$ORCLMedAI 8/10

Larry Ellison adds $9.2 billion in Oracle shares as loan collateral

Oracle (NYSE:ORCL) co-founder Larry Ellison pledged 67 million additional shares, worth $9.2 billion, as collateral for personal loans, increasing his pledged shares by 19% since 2025. Ellison now has 36% of his Oracle holdings pledged, with shares closing at $137.10. He is financing his son's $111 billion acquisition of Warner Bros. Discovery (NASDAQ:WBD) with a $47 billion equity commitment.

$NFLXMed

Netflix (NFLX)’s YouTube Problem Is Becoming Harder to Dismiss

Netflix (NFLX) faces growing competition from YouTube, with YouTube's U.S. TV viewership share reaching 14.2% in July, compared to Netflix's 7.8%. HSBC and Wells Fargo downgraded Netflix, citing YouTube's increasing share and Netflix's weakening viewership. Netflix's Q2 hedge fund support declined to 121 from 144 in Q1. Netflix reported 97 billion viewing hours in the first half of 2026, but analysts warn of potential increased costs to compete with YouTube.

$BKRMed

Baker Hughes wins dual equipment contracts to expand Venture Global’s Plaquemines LNG facility and Cloud Connector Pipeline in Louisiana

Baker Hughes won two contracts from Venture Global LNG for equipment to expand the Plaquemines LNG facility and the Cloud Connector Pipeline in Louisiana. The deals include 13 gas compression systems and 8 liquefaction modules, totaling over 100 million metric tons per year of LNG production capacity supported by Baker Hughes. According to Baker Hughes, this collaboration is part of a broader effort to enhance US LNG export capacity and energy security.